These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28540167)

  • 61. Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV)
    Ge FL; Si LL; Yang Y; Li YH; Lv ZL; Liu WH; Liao H; Wang J; Zou J; Li L; Li H; Zhang ZL; Wang JB; Lu XC; Xu DP; Bai ZF; Liu Y; Xiao XH
    Front Pharmacol; 2021; 12():756975. PubMed ID: 34776974
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Establishment of an HBV chronic hepatitis B infection mouse model by vivo transduction of HBV cccDNA].
    Zhao T; Li X; Yin W; Cai X; Zhang W; Chen F; Lai G; Huang A
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):260-5. PubMed ID: 25173223
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Anti-HBc Screening of Blood Donors in Bangladesh: Relevance to Containment of HBV Propagation.
    Jahan M; Islam MA; Akbar SM; Takahashi K; Tabassum S; Rahman A; Haque MA; Biswas J; Mishiro S; Al-Mahtab M
    J Clin Exp Hepatol; 2016 Jun; 6(2):115-8. PubMed ID: 27493459
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death receptor-1 expression in patients with chronic hepatitis B.
    Gu XB; Yang XJ; Hua Z; Lu ZH; Zhang B; Zhu YF; Wu HY; Jiang YM; Chen HK; Pei H
    Chin Med J (Engl); 2012 Apr; 125(8):1434-8. PubMed ID: 22613649
    [TBL] [Abstract][Full Text] [Related]  

  • 65. HBV-specific lymphoproliferative and cytokine responses in patients with chronic hepatitis B.
    Vingerhoets J; Michielsen P; Vanham G; Bosmans E; Paulij W; Ramon A; Pelckmans P; Kestens L; Leroux-Roels G
    J Hepatol; 1998 Jan; 28(1):8-16. PubMed ID: 9537868
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
    Demirören K; Kocamaz H; Doğan Y
    Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.
    Shao X; Ma J; Jia S; Yang L; Wang W; Jin Z
    Front Cell Infect Microbiol; 2017; 7():472. PubMed ID: 29181338
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 73. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
    Lei YC; Tian YJ; Ding HH; Wang BJ; Yang Y; Hao YH; Zhao XP; Lu MJ; Gong FL; Yang DL
    World J Gastroenterol; 2006 Dec; 12(46):7488-96. PubMed ID: 17167839
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus.
    Marinos G; Torre F; Chokshi S; Hussain M; Clarke BE; Rowlands DJ; Eddleston AL; Naoumov NV; Williams R
    Hepatology; 1995 Oct; 22(4 Pt 1):1040-9. PubMed ID: 7557849
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
    Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
    Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association of cytokines with hepatitis B virus and its antigen.
    Li MH; Chen QQ; Zhang L; Lu HH; Sun FF; Zeng Z; Lu Y; Yi W; Xie Y
    J Med Virol; 2020 Dec; 92(12):3426-3435. PubMed ID: 32662892
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
    Schödel F; Peterson D; Milich D
    Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
    Lee MH; Lee DM; Kim SS; Cheong JY; Cho SW
    J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.